SCHEMBL4786441

SCHEMBL4786441

Cn1nc(Nc2cccc(Cl)c2)c2cc(Cl)sc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
KDM4E B2RXH2 4/20 0.48
MAPT P10636 4/20 0.48
HPGD P15428 4/20 0.48
HSD17B10 Q99714 4/20 0.48
CYP1A2 P05177 3/20 0.48
CYP3A4 P08684 3/20 0.48
CYP2C9 P11712 2/20 0.48
CYP2C19 P33261 2/20 0.48
MAPK1 P28482 2/20 0.48
POLB P06746 1/20 0.48
HSP90AA1 P07900 1/20 0.48
TTBK1 Q5TCY1 1/20 0.44
TTBK2 Q6IQ55 1/20 0.44
MKNK1 Q9BUB5 2/20 0.43
FADS1 O60427 6/20 0.43
EGFR P00533 5/20 0.43
GAA P10253 2/20 0.42
LCK P06239 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4740878 0.78 EGFR (0.51) MEN1KMT2AKDM4EMAPTHPGD
SCHEMBL4786745 0.78 GAA (0.53) MEN1KMT2AKDM4EMAPTHPGD
SCHEMBL4785908 0.75 HPGD (0.50) MEN1KMT2AKDM4EMAPTHPGD
SCHEMBL4787234 0.75 KDM4E (0.53) MEN1KMT2AKDM4EMAPTHPGD
SCHEMBL4785974 0.74 FADS1 (0.55) MEN1KMT2AKDM4EMAPTHPGD
SCHEMBL4740887 0.74 MEN1 (0.56) MEN1KMT2AKDM4EMAPTHPGD
SCHEMBL20674205 0.73 KDM4E (0.41) MEN1KMT2AKDM4EMAPTHPGD
SCHEMBL4739653 0.72 MEN1 (0.45) MEN1KMT2AKDM4EMAPTHPGD
SCHEMBL4742065 0.72 FADS1 (0.59) MEN1KMT2AKDM4EMAPTHPGD
SCHEMBL4738586 0.71 FADS1 (0.58) MEN1KMT2AKDM4EMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089310-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO claimed
WO-2008089307-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO claimed
US-20080200458-A1 Methods and compositions for the treatment of body composition disorders LEXICON PHARMACEUTICALS, INC. 2008-08-21 US disclosed
US-20080194557-A1 Methods and compositions for the treatment of pain, inflammation and cancer LEXICON PHARMACEUTICALS, INC. 2008-08-14 US disclosed
WO-2008089310-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO disclosed
WO-2008089307-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194557-A1 Methods and compositions for the treatment of pain, inflammation and cancer TNF, IL6, CXCL8 MEN1 3245/4885KMT2A 3920/4885KDM4E 4283/4885
US-20080200458-A1 Methods and compositions for the treatment of body composition disorders CPT1B, CPT1A, SHBG MEN1 1919/4885KMT2A 3148/4885KDM4E 3229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.